Lessons from the Atomic Bomb About Secondary MDS

Myelodysplastic syndromes (MDSs) is a hematological neoplasm defined by ineffective hematopoiesis, dysplasia of hematopoietic cells, and risk of progression to acute leukemia. MDS occurs as de novo or secondary, and chemoradiotherapy for cancers is thought to increase the risk of MDS among patients....

Full description

Saved in:
Bibliographic Details
Published inCurrent hematologic malignancy reports Vol. 9; no. 4; pp. 407 - 411
Main Authors Hata, Tomoko, Imanishi, Daisuke, Miyazaki, Yasushi
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.12.2014
Subjects
Disease Progression
Female
Geriatrics/Gerontology
Hematology
Humans
Male
Medicine
Medicine & Public Health
Myelodysplastic Syndromes (M Sekeres
Myelodysplastic Syndromes - complications
Myelodysplastic Syndromes - etiology
Nuclear Weapons
Oncology
Section Editor
Atomic bomb survivors
Hematopoiesis
Hematopoietic cells
Myelodysplastic syndromes
Online AccessGet full text

Cover

More Information
Summary:Myelodysplastic syndromes (MDSs) is a hematological neoplasm defined by ineffective hematopoiesis, dysplasia of hematopoietic cells, and risk of progression to acute leukemia. MDS occurs as de novo or secondary, and chemoradiotherapy for cancers is thought to increase the risk of MDS among patients. Recently, an epidemiological study for MDS among A-bomb survivors was performed, and it clearly demonstrated that the exposure to external radiation significantly increased the risk of MDS. Precise epidemiological data among survivors have revealed important clinical factors related to the risk of leukemias. In this review, by comparing data for secondary MDS and leukemia/MDS among survivors, several factors which would affect the risk of MDS, especially secondary MDS, are discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1558-8211
1558-822X
DOI:10.1007/s11899-014-0235-0